Home / Recalls / IBSA PHARMA INC / D-0333-2023

D-0333-2023 Class II Terminated

Recalled by IBSA PHARMA INC — Parsippany, NJ

Recall Details

Product Type
Drugs
Report Date
March 1, 2023
Initiation Date
January 30, 2023
Termination Date
October 31, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0140-5

Reason for Recall

Subpotent Drug

Distribution Pattern

Nationwide in the USA.

Code Information

Lot #: 220855, Exp. 2/2024.

Other recalls by IBSA PHARMA INC

  • D-0341-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches (January 30, 2023)
  • D-0335-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL; 6 pouches (January 30, 2023)
  • D-0337-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL; 6 pouches (January 30, 2023)
  • D-0332-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL; 6 pouches (January 30, 2023)
  • D-0343-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL; 6 pouches (January 30, 2023)
  • D-0339-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL; 6 pouche (January 30, 2023)
  • D-0345-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL; 6 pouches (January 30, 2023)
  • D-0336-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL; 6 pouche (January 30, 2023)
  • D-0340-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL; 6 pouches (January 30, 2023)
  • D-0338-2023 Class II — TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL; 6 pouches (January 30, 2023)